← Leaderboards
Stephen Gire
Nextgenjane, Inc.
$2,537,619
Attributed
$2,537,619
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,537,619 · 2
By mechanism
R44$2,537,619 · 2
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Genomics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$405,398,682
- Scott Topper · Broad Institute, Inc.$153,234,573
- Lynn Briscoe · Leidos Biomedical Research, Inc.$137,892,657
- Leonard Freedmand · Leidos Biomedical Research, Inc.$96,686,407
- Dwayne Forquer · Leidos Biomedical Research, Inc.$50,844,487
- Scott Andrew Sutherland · Vignet, Inc.$37,105,117
Research focus
GenomicsLaparoscopic Surgical ProceduresEarly DiagnosisEvaluationHistologicLaboratoriesDetectionDisease ProgressionDiagnosticEnrollmentBiological MarkersDiagnosis StandardDiagnosisHormonesConfidence IntervalsComplexCostDisease DiagnosisCandidate MarkerDatabasesEndometrialEndometriosisCollectionLaparoscopy
Grant awards (4)
Performance evaluation of a non-invasive menstrual test for endometriosis in infertility patients$759,944
R44 · FY2025 · HD · contact PI
Developing a non-invasive, definitive diagnostic for endometriosis using biomarkers in menstrual effluence$401,530
R44 · FY2023 · HD · contact PI
Developing a non-invasive, definitive diagnostic for endometriosis using biomarkers in menstrual effluence$1,108,476
R44 · FY2022 · HD · contact PI
Developing a non-invasive, definitive diagnostic for endometriosis using biomarkers in menstrual effluence$267,669
R44 · FY2020 · HD · contact PI